Morten Haugen/LinkedIn
Sep 19, 2025, 16:48
Morten Haugen Warns of IgG Risks for High-Frequency Plasma Donors
Morten Haugen, Resident physician specializing in immunology and transfusion medicine at Oslo University Hospital, shared a post on LinkedIn:
“New evidence on plasma donation frequency:
- The first paper from my PhD-work is now published in Vox Sanguinis! In this randomized trial we found that
High-frequency (3×/2 weeks) and regular-frequency (1×/2 weeks) plasma donation significantly lowered total serum protein and immunoglobulin G. - Up to 26% of high-frequency donors dropped below the IgG safety threshold of 6.0 g/L, even when starting with normal levels of more than 8.0 g/L in most donors.
- Many plasma proteins had not recovered 4 weeks after the last donation.
These findings highlight the need for careful donor monitoring and further research into long-term health effects.
Full article here

Thanks to the volunteer blood donors, the research team and my co-authors Karin Magnussen, Tor Strand and Lise Sofie Nissen-Meyer for making the study possible.”
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 16:46Moaz Abouelmagd: Key Findings from a Large Network Meta-Analysis of IV Thrombolytics in Acute Ischemic Stroke
-
Jun 11, 2026, 16:37Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis
-
Jun 11, 2026, 16:34Joao Mariano Pego: Advancing Coagulation Diagnostics Through Standardized Thrombin Generation
-
Jun 11, 2026, 16:33Ifeanyichukwu Ifechidere: Nobody Talks About Thrombosis in Sickle Cell Disease
-
Jun 11, 2026, 16:31Karim Mahawish: Ischaemic Stroke Despite Anticoagulation in Atrial Fibrillation
-
Jun 11, 2026, 16:29Salim Virani: The 2026 ACC/AHA Multisociety Dyslipidemia Guideline Promotes Early Prevention
-
Jun 11, 2026, 16:25Toyosi Onwuemene: What Clinicians Reveal About Bleeding and Clotting Care
-
Jun 11, 2026, 16:20Tejas Ahire: Rh Incompatibility – A Small Blood Group Difference with Big Clinical Impact
-
Jun 11, 2026, 16:19Jack Shuang Hou: Bayer Advances Asundexian as EMA Reviews New Option for Preventing Recurrent Ischemic Stroke